Economic Evaluation of Fulvestrant 500mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden

Economic Evaluation of Fulvestrant 500mg Compared to Generic Aromatase Inhibitors in Patients... PharmacoEconomics Open (2017) 1:279–290 https://doi.org/10.1007/s41669-017-0031-6 ORIGINAL RESEARCH ARTICLE Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden 1 1 1 2 • • • • Ugne Sabale Mattias Ekman Daniel Thunstro¨m Claire Telford Christopher Livings Published online: 1 June 2017 The Author(s) 2017. This article is an open access publication Abstract €33,808, €33,883, and €49,225 per QALY with incre- Objectives In Sweden, breast cancer (BC) represents 30% mental costs of €13,283, €14,986, and €13,862, and of newly diagnosed cancers and is the most common incremental QALYs of 0.393, 0.442, and 0.282, respec- cancer in women. For hormone-dependent BC, endocrine tively. Incremental cost per life-year (LY) gained €21,312 therapies varying in efficacy and price are available. The (incremental LY of 0.623), €20,338 (incremental LY of aim of this study is to assess the cost effectiveness of 0.737), and €27,854 (incremental LY of 0.498) for fulvestrant 500 mg as a second-line hormonal therapy for respective comparators. Applying the upper and lower postmenopausal women with estrogen receptor-positive credible intervals for PFS/OS from the meta-analysis had metastatic or locally advanced BC versus letrozole, anas- the greatest effect on the ICER in the sensitivity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics - Open Springer Journals

Economic Evaluation of Fulvestrant 500mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden

Loading next page...
 
/lp/springer_journal/economic-evaluation-of-fulvestrant-500mg-compared-to-generic-aromatase-igkRarviZU
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes
ISSN
2509-4262
eISSN
2509-4254
D.O.I.
10.1007/s41669-017-0031-6
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial